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Summary box
What is already known about this subject?
 ► Gastrointestinal (GI) cancer is the cause of iron defi-
ciency anaemia (IDA) in 8%–10% of adult men and 
postmenopausal women.
 ► The risk of GI cancer in IDA is influenced by age, 
sex and Hb.
 ► Faecal immunochemical testing (FIT) in IDA may be 
of value in identifying underlying GI cancer.
What are the new findings?
 ► Age, sex and Hb are confirmed as strong predictors 
of the risk of GI cancer in IDA.
 ► Mean cell volume is an additional independent pre-
dictor of the risk.
 ► In combination, these four predictors can identify 
10% of the referred IDA population who are at ultra- 
low risk of GI cancer.
 ► FIT is predictive of GI cancer risk in high- risk indi-
viduals with IDA, though the sensitivity is low.
 ► An app can facilitate the use of the model in a clin-
ical setting.
How might it impact on clinical practice in the 
foreseeable future?
 ► The predictive model may allow the use of inves-
tigational resources to be rationalised in IDA, by 
fast- tracking high- risk cases and, with appropriate 
safeguards, avoiding invasive investigation alto-
gether in those at ultra- low predicted risk.
 ► The app is intended to facilitate the use of this mod-
el in a clinical setting.
AbSTrACT
Objective To refine and validate a model for predicting 
the risk of gastrointestinal (GI) cancer in iron deficiency 
anaemia (IDA) and to develop an app to facilitate use in 
clinical practice.
Design Three elements: (1) analysis of a dataset of 2390 
cases of IDA to validate the predictive value of age, sex, 
blood haemoglobin concentration (Hb), mean cell volume 
(MCV) and iron studies on the probability of underlying 
GI cancer; (2) a pilot study of the benefit of adding faecal 
immunochemical testing (FIT) into the model; and (3) 
development of an app based on the model.
results Age, sex and Hb were all strong, independent 
predictors of the risk of GI cancer, with ORs (95% CI) 
of 1.05 per year (1.03 to 1.07, p<0.00001), 2.86 for 
men (2.03 to 4.06, p<0.00001) and 1.03 for each g/L 
reduction in Hb (1.01 to 1.04, p<0.0001) respectively. 
An association with MCV was also revealed, with an OR 
of 1.03 for each fl reduction (1.01 to 1.05, p<0.02). The 
model was confirmed to be robust by an internal validation 
exercise. In the pilot study of high- risk cases, FIT was also 
predictive of GI cancer (OR 6.6, 95% CI 1.6 to 51.8), but 
the sensitivity was low at 23.5% (95% CI 6.8% to 49.9%). 
An app based on the model was developed.
Conclusion This predictive model may help rationalise 
the use of investigational resources in IDA, by fast- 
tracking high- risk cases and, with appropriate safeguards, 
avoiding invasive investigation altogether in those at ultra- 
low predicted risk.
IntroductIon
Iron deficiency anaemia (IDA) is a common 
clinical problem, with an overall incidence in 
western populations approaching two cases 
per 1000 pa, and a considerably higher age- 
specific incidence in those over the age of 70 
years.1 2 More than a quarter of men and post-
menopausal women with IDA have significant 
underlying gastrointestinal (GI) pathology, 
and malignancy is by far the most important 
cause, found in 8%–10% of cases.3–5 IDA is 
an important indicator of GI cancer, partic-
ularly cancer of the right colon, as it often 
occurs before any other clinical pointer to 
the diagnosis.6
The IDA clinic at Poole Hospital is the 
point of referral for the many patients with 
IDA who have minimal or no symptoms to 
indicate the nature or location of the under-
lying cause of iron deficiency and for whom 
further assessment is felt to be warranted. 
Basic patient data have been collected since 
inception for the purpose of clinical care, 
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audit and service evaluation. The referral rate to the IDA 
clinic now exceeds 400 new patients per annum.2 7
In view of the possibility of underlying GI cancer, it is 
current standard practice to advise urgent investigation of 
at- risk subjects with IDA, which in the first instance gener-
ally involves gastroscopy and colonoscopy/colonography 
to examine the upper and lower GI tract, respectively.8 
These investigations are however expensive and labour 
intensive, and not entirely without risk of problems 
and complications, particularly in those with significant 
comorbidities. Furthermore, over 80% of investigations 
for IDA will not reveal significant pathology.
As individuals with IDA are likely to vary in their indi-
vidual likelihood of malignancy, a simple but reliable 
preinvestigation predictor of GI cancer risk would help 
considerably with patient counselling. Risk stratification 
could also rationalise the use of resources, with prioritisa-
tion of high- risk subjects for fast- track investigation, and 
perhaps avoidance of invasive investigation altogether in 
particularly low- risk individuals.
Previous work by our group and others9 10 has demon-
strated that three simple and objective clinical vari-
ables—age, sex and blood haemoglobin concentration 
(Hb)—appear to be independent predictors of under-
lying GI cancer in IDA. In the IDIOM (Iron Deficiency 
as an Indicator of Malignancy (IDIOM) study of an IDA 
cohort of 720, the combination of these variables was 
used to derive a score corresponding to the percentage 
probability of underlying GI malignancy, which ranged 
from less than 2% in low- risk subgroups to more than 
20% in high- risk subgroups.10 These studies9 10 do 
however have the shortcomings that both were retrospec-
tive in design and lacked an a priori hypothesis, simply 
because there was insufficient evidence on which to base 
such a hypothesis.
The aims of the study reported here were threefold. 
First, to provide prospective validation of the indepen-
dent variables identified in the original IDIOM study as 
predictors of underlying GI cancer, by analysing a much 
larger IDA cohort, and to determine whether mean cell 
volume (MCV) and iron studies (transferrin saturation/
serum ferritin) might prove to be additional predictors 
of risk. Second, to undertake a pilot study to explore 
whether faecal immunochemical testing (FIT) for small 
quantities of human haemoglobin in faecal specimens 
can improve risk stratification still further. The rationale 
for this hypothesis is that chronic low- grade blood loss 
from the tumour bed is assumed to be the major factor 
contributing to the development of IDA in subjects with 
GI cancer. Third, to develop an app for use in the clinical 
setting to provide an instant assessment of GI cancer risk 
following the input of simple clinical data.
Method
Validation study
The first part of the study involved a detailed assess-
ment of clinical data for subjects referred for assessment 
in the Poole IDA clinic with confirmed iron deficiency 
by standard laboratory criteria (transferrin saturation 
<15% and/or serum ferritin concentration less than 
the lower limit of the reference interval for the labora-
tory at the time) who were assessed between 2004 and 
2018 inclusive,2 incorporating some cases included in a 
previous report.10 Cases presenting in 2004–2016 formed 
the training dataset, while those presenting in 2017–2018 
provided the validation dataset. Developing the model 
using the training dataset was carried out in 2018, before 
receiving the validation dataset.
The final datasets included age at presentation and 
sex, blood test results (Hb, MCV and iron studies) and 
the diagnostic findings on standard investigation of the 
upper and lower GI tract. Data sets were complete for age, 
sex, Hb, MCV and presence/absence of GI malignancy. 
As results were available for both transferrin saturation 
and serum ferritin in only 36.8% of the study population, 
iron deficiency was analysed as a dichotomous variable, 
being ‘severe’ (arbitrarily defined as a transferrin satu-
ration <10% and/or a serum ferritin <10 µg/L) or ‘non- 
severe’ (criteria for severe deficiency not met).
Anonymised data were analysed to assess whether the 
five clinical parameters could usefully predict the like-
lihood of GI malignancy on subsequent investigation. 
Data preparation involved cleaning the data by checking 
and correcting any unusual values, removing duplicate 
entries and retaining only the first record for any patient 
referred more than once to the IDA clinic. A training 
dataset was used to derive the prediction model, which 
was then tested on a validation dataset. As this was a 
secondary analysis of anonymised data, formal Research 
Ethics approval was not required for this element of the 
study.
Logistic regression models were run for each of the 
predictors separately, with GI cancer as the outcome. 
When any significant association was found between a 
predictor and GI malignancy (p<0.05), this predictor 
was added to a multivariable logistic regression model. 
Smoothed scatter plot, Cook’s distance and standardised 
residual errors, variance inflation factor, Akaike infor-
mation criterion, analysis of variance χ2 test, pseudo R2 
and the Hosmer- Lemeshow test were used to check the 
validity of the fitted logistic regression model and the 
goodness of fit.11
To assess the performance of the fitted model derived 
from the training dataset, we examined how well it 
predicted GI cancer in the validation dataset. Cut- off 
metrics12 13 were used to assess performance, because 
traditional evaluations such as overall accuracy were not 
appropriate14 in view of the small percentage of partic-
ipants with GI malignancy in the study. A classification 
cut- off probability (decision threshold) was identified 
using the training data, in which a value above that cut- 
off indicates the presence and a value below the absence 
of GI cancer. The prediction model was then tested on 
the validation dataset using this cut- off. Three optimal 
prediction cut- offs were selected :
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Figure 1 Receiver operating characteristic curve for the 
training dataset, showing the three optimal cut- off points 
defined in the text: cut- off 1=1.5%, cut- off 2=7.4%, cut- off 
3=11.1%. AUC, area under curve.
1. Cut- off 1: the highest cut- off at which the negative pre-
dictive value (NPV) remains 100%. NPV is the number 
of negative cases that were correctly classified divided 
by the total number of negative cases predicted.15 This 
cut- off identifies subjects who are at ultra- low risk of 
GI cancer.
2. Cut- off 2: at which geometric mean (G mean) of sensi-
tivity and specificity is highest.16 G mean is calculated 
from the formula: 
 
√(
sensitivity ∗ specificity)
 
.17 18
3. Cut- off 3: the lowest cut- off at which the positive pre-
dictive value (PPV) remains in the upper quartile (ie, 
the point below which 75% of PPVs lie). PPV is the 
number of positive cases that were correctly classified 
divided by the total number of positive cases predict-
ed.15 This cut- off identifies patients who are at high 
risk of GI cancer.
Receiver operating characteristic (ROC) was used to 
compare and visualise the effectiveness of the predic-
tive model at separating positive and negative classes 
according to each cut- off.19
FIt pilot study
In brief, 80 subjects were prospectively identified who 
fulfilled all of the following criteria: (1) confirmed IDA, 
(2) high GI cancer risk based on age and Hb (70 years 
or over and <100 g/L, respectively)10 and (3) listed for 
investigation with gastroscopy and colonoscopy/colo-
nography. Each was invited to provide a faecal sample 
for FIT prior to invasive investigation, using the Hema- 
screen SPECIFIC kit (Alpha Laboratories, Eastleigh, 
UK); the manufacturer’s published analytical detection 
limit for this test is 50 µg Hb/g faeces.20 FIT analysis was 
undertaken without knowledge of the outcome of GI 
investigation.
App development
To simplify utilisation of the prediction model in clin-
ical settings, a web- based application was developed. R 
(V.3.6.1), RStudio (V.1.2.5001), R Shiny and DT packages 
were used to run the statistical analysis and to build the 
app.
results
Validation study
Over 2800 subjects with iron deficiency were seen in the 
IDA clinic during the study period. Excluding those in 
whom investigations were not completed due to patient 
preference, frailty or concurrent illness, and those whose 
records were incomplete, left 2390 subjects for detailed 
analysis. For the validation study, there were 1879 in the 
training dataset and 511 in the validation dataset.
The total study group comprised 1528 women and 862 
men (a sex ratio of 1.8), with a median age of 71 years 
(IQR: 59–79 years) and mean (SD) values for Hb and 
MCV of 103 (17.4) g/L and 80.0 (9.1) fL, respectively. 
The arbitrary criteria for severe iron deficiency were 
met by 57% of the study population. GI carcinoma was 
identified in 200 individuals in the study group, giving an 
overall prevalence of 8.4%. Of those, 172 (86%) were in 
the lower GI tract, and of those, 140 (81%) were in the 
right colon.
Comparison of the training and validation datasets 
revealed marginally higher values for mean Hb (102 g/L 
vs 106 g/L, p<0.001) and mean MCV (79.4 fL vs 82.2 fL, 
p<0.001) in the latter. This is consistent with changes 
in the characteristics of our IDA population over time 
reported elsewhere.2 There were otherwise no significant 
differences between the training and validation datasets 
for any of the key variables.
Analysis of the training dataset confirmed that age, sex 
and Hb were all strong, independent predictors of the 
risk of GI cancer. MCV was also predictive though there 
was greater variability, resulting in a wider CI. There was 
no significant relationship with the results of iron studies. 
The final multiple binary logistic regression model was 
therefore constructed according to the formula: ln(GI_
cancer) ~ β0 + β1age + β2sex + β3Hb + β4MCV. Statistical 
assessment of validity and goodness of fit of the logistic 
regression model based on the criteria outlined in the 
Method section was satisfactory.
The ORs (95% CI, p value) for the four predictive vari-
ables were as follows:
 ► Age: 1.05 per year (1.03 to 1.07, p<0.00001).
 ► Sex: 2.86 for men (2.03 to 4.06, p<0.00001).
 ► Hb: 1.03 for each g/L reduction (1.01 to 1.04, 
p<0.0001).
 ► MCV: 1.03 for each fL reduction (1.01 to 1.05, 
p<0.02).
The ROC curve for the training dataset shows the true 
positive rate on Y axis (sensitivity) and false positive rate 
on X axis (1- specificity), along with the three optimal cut- 
offs described in the Method section (figure 1). Using the 
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Table 2 Distribution of gastrointestinal (GI) cancers by 
faecal immunochemical testing (FIT) result in 62 subjects 
with IDA at predicted high risk
GI cancer
Negative (n=45) Positive (n=17)
FIT result
  Negative (n=56) 43 13
  Positive (n=6) 2 4
IDA, iron deficiency anaemia.
Table 1 Characteristics of the three optimal cut- off points for predicted probability of GI cancer, as applied to the training 
and validation datasets
Threshold Criterion Training dataset (%) Validation dataset (%)
Optimal cut- off 1
(1.5%)
NPV=100% Sensitivity (95% CI) 100.0 (97.7 to 100.0) 100.0 (91.8 to 100.0)
NPV (95% CI) 100.0 (98.0 to 100.0) 100.0 (95.1 to 100.0)
Optimal cut- off 2
(7.4%)
G mean Sensitivity (95% CI) 75.8 (68.3 to 82.3) 79.1 (63.9 to 89.9)
Specificity (95% CI) 63.2 (60.9 to 65.5) 67.7 (63.3 to 71.9)
Optimal cut- off 3
(11.1%)
PPV in highest quartile Sensitivity (95% CI) 56.1 (47.9 to 63.9) 60.5 (44.4 to 75.0)
PPV (95% CI) 18.6 (15.2 to 22.4) 23.9 (16.2 to 32.9)
GI, gastrointestinal; G mean, geometric mean; NPV, negative predictive value; PPV, positive predictive value.
Figure 2 Heatmap showing the probability of 
gastrointestinal (GI) cancer in the overall IDA cohort (n=2390) 
according to age, sex, blood haemoglobin concentration (Hb: 
g/L) and mean cell volume (MCV: fL). The darker the box, 
the higher the GI cancer risk—as shown on the risk key. The 
risk ranges are based on positive predictive value quartiles, 
with the lowest quartile divided in two. IDA, iron deficiency 
anaemia.
regression model to calculate predicted GI malignancy 
risk, cut- off 1 (risk 1.5%) was able to stratify about 10% 
of both cohorts into an ultra- low risk subgroup. Cut- off 
2 (risk 7.4%) maximised G mean in the training dataset 
(69.2%; 95% CI 21.8% to 219.9%) and gave a comparable 
value in the validation dataset (73.2%; 95% CI 27.4% to 
195.6%), with closely overlapping CIs and similar values 
for sensitivity and specificity. Cut- off 3 (risk 11.1%) strati-
fied about 25% of both cohorts into a high risk subgroup. 
These results (summarised in table 1) demonstrate that 
the model is robust in predicting the risk of underlying 
GI cancer in a new IDA dataset collected in a different 
time period.
The striking effect of combining the predictive vari-
ables on predicted risk is displayed in heat- map format 
in figure 2. This demonstrates the high risk in all older 
men with IDA regardless of haematology findings, and 
the extremely low risk in younger women with marginal 
anaemia and a normal MCV. None of the individuals with 
a risk predicted by the model of less than 1.5% proved to 
have GI cancer on investigation—accounting for 10% of 
the whole cohort.
FIt pilot study
A total of 62 subjects at predicted high risk of GI malig-
nancy returned an adequate faecal sample for FIT analysis 
and completed their scheduled investigations. Of these 
17 (27.4%) proved on subsequent investigation to have a 
GI cancer (upper GI - 2, right colon - 14, left colon - 1). A 
summary of the results is shown in table 2 - FIT positivity 
was associated with GI malignancy (OR=6.6, 95% CI 1.6 
to 51.8), and this significant association persisted after 
adjustment for the IDIOM score variables of age, sex, Hb 
and MCV. However, the sensitivity of FIT for GI cancer 
was low at 23.5% (95% CI 6.8% to 49.9%), and this only 
increased to 26.7% (95% CI 7.8% to 55.1%) with exclu-
sion of the upper GI cancers.
App development
An app (Predict GI Cancer in IDA) was developed based 
on the model. This generates an estimate of GI cancer 
risk (with 95% CI) following the insertion of data for 
the four key variables: age, sex, Hb and MCV. The whole 
process takes just a few seconds, which lends itself to use 
in busy clinical settings, and our intention is to make the 
app freely available following Medicines and Healthcare 
Products Regulatory Agency approval and CE marking. A 
screenshot from the app is shown in figure 3.
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Figure 3 A screenshot from the app Predict GI Cancer in IDA.
dIscussIon
IDA is a problem commonly encountered in clinical prac-
tice, and the prevalence of underlying GI cancer in IDA is 
the primary justification for urgent investigation.3–8 Bidi-
rectional endoscopy (BDE), combining gastroscopy and 
colonoscopy in the same session, is generally accepted 
as the most efficient method of assessing the GI tract 
unless there are clear clinical clues as to the cause.7 It 
does however carry a small but significant risk of compli-
cations, particularly in the elderly and those with major 
comorbidities, and it is important to consider the risk–
benefit ratio for the investigation of IDA on an individual 
case basis.
BDE is also labour intensive, taking up to an hour to 
complete for each patient, yet over 90% of procedures 
for IDA will not reveal malignancy. Because it is common, 
IDA is a major drain on investigational resources, 
accounting for a substantial proportion of the workload 
in many endoscopy units, with estimates in the region 
of 20% of all diagnostic examinations.2 Any manoeuvre 
to safely reduce the number of necessary investigations 
has the potential to make a substantial positive impact on 
both costs and waiting times.
There is therefore the need for a simple and reliable 
pretest predictor of the risk of underlying malignancy 
that is sufficiently discriminating to be clinically useful 
for patient- centred counselling. Effective risk stratifica-
tion is a potentially useful clinical tool for two reasons. 
First, it allows the identification of a high- risk subgroup 
who warrant accelerated investigation and can be advised 
accordingly. Second, it reveals individuals at very low risk 
who are unlikely to benefit from invasive investigation and 
may wish to make a considered decision not to proceed. 
The development of an app means that GI cancer risk 
can be computed in a few seconds, with obvious benefit 
in busy clinical settings.
The findings of this study have limitations. First, the 
predicted GI cancer risk is in all cases greater than 0% 
and less than 50%. Second, while GI cancer is the most 
important cause of IDA, it is not the only one, and we 
know from previous work that the model is not useful 
in predicting the likelihood of these other causes.10 For 
these two reasons, the model can never be more than a 
guide to the need for invasive investigation. Finally, while 
large the study is based on a single- centre experience, 
raising the question of universal applicability. Work is 
underway to address this by validating the model on a 
totally independent external IDA dataset.
The study reported here builds on previous reports 
from our group and others9 10 by confirming in a much 
larger IDA cohort that age, sex and Hb are all strong 
independent predictors of the risk of GI cancer. It also 
reveals an independent relationship with MCV – this has 
not been evident in previous analyses9 10 apart from a 
single report on a very small cohort21, and has perhaps 
emerged in this study because of the substantially larger 
cohort size.
The predictive value of age and sex is not unexpected, 
given that the incidence of the major GI malignancies 
rises steeply after the age of 70 years, particularly in 
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men.22 23 It may be that Hb is predictive of GI cancer risk 
simply because the nature of the pathology means that 
GI malignancy is disproportionately more likely than the 
other (non- malignant) causes of IDA to lead to greater 
degrees of anaemia.
The explanation for the effect of MCV on risk is less 
clear. It might perhaps reflect either chronicity or severity 
of the depletion of body iron stores in those with under-
lying GI cancer. Although the analysis of iron studies does 
not support the latter explanation, ferritin and trans-
ferrin saturation are surrogate markers of iron stores 
and may be influenced by other factors. Serum ferritin in 
particular is an acute phase protein and may therefore be 
spuriously high in individuals with malignancy.
IDA is a particular challenge in the elderly,24 as this is 
the age group with the highest prevalence of IDA, and 
the highest risk of underlying GI cancer.2 However, it is 
also the age group at highest risk of complications from 
invasive investigation or from subsequent surgery if 
required—and debatably the least to gain from interven-
tion. Management planning in this situation needs to be 
made on a case- by- case basis, and while only one element 
of the risk–benefit equation, an accurate prediction of 
GI cancer risk can only help the individual concerned to 
reach the right decision.
One of the striking findings of the study is the identifi-
cation of subgroups with a very low GI cancer risk. Indeed, 
in the 10% of the total cohort with a predicted risk of less 
than 1.5%, no GI cancers were found. It is important to 
note that this includes some postmenopausal women, as 
shown in figure 2. The finding is unlikely to be the result 
of referral bias, as younger women with mild anaemia 
are the IDA subgroup least likely to be referred unless 
there was some other reason for suspecting GI disease, 
for example, a strong family history of GI cancer.
It is important to stress that ‘low- risk’ does not equate 
to ‘no risk’ and that additional fail- safes need to be incor-
porated before advocating a no investigation policy for 
low- risk subgroups, a process known as diagnostic safety 
netting.25 The first safety net for ‘low risk’ IDA is ensuring 
a full and sustained haematological response to a course 
of iron replacement therapy. This should already be stan-
dard practice and has been shown to predict a very low 
risk of missed pathology following BDE in those with 
IDA.26
A second potential safety net is testing for tiny quan-
tities of blood in a faecal sample using FIT. The devel-
opment of FIT is undoubtedly a major step forward in 
the risk assessment of patients in primary care presenting 
with lower GI symptoms and in screening programmes 
for colorectal cancer (CRC) such as the NHS England 
Bowel Cancer Screening Programme.27–30 It has a greater 
sensitivity for CRC (the most common GI cancer under-
lying IDA) than guiac- based testing for faecal occult 
blood31 32 and has been shown to be of some predictive 
value for GI cancer in the IDA population without clin-
ical risk scoring.27 33 34 The situation might be analogous 
to established practice in the diagnosis of pulmonary 
embolism, where it is accepted that those with a low clin-
ical probability score and a low test result (for d- dimer) 
have such a vanishingly low risk that further investigation 
is not warranted.35
The pilot study reported here demonstrates that in a 
high- risk IDA subgroup FIT can predict the presence of 
CRC, but the sensitivity of 26.7% is disappointingly low. 
Numbers are obviously small, but this suggests that FIT 
may not be a particularly helpful adjunct to the IDIOM 
score in predicting GI cancer risk, at least at the 50 µg 
Hb/g faeces detection threshold. It may be that FIT at a 
lower detection threshold might improve the sensitivity 
for CRC in IDA without an unacceptable fall in speci-
ficity, although a recent meta- analysis demonstrates only 
a marginal improvement in sensitivity on reducing the 
FIT threshold from ≥30 to 10 µg Hb/g faeces, despite 
more than doubling the number of positive results.36
The low sensitivity found here may at first sight seem 
surprising, but it is important to bear in mind that while 
right- sided lesions account for about 35% of all CRCs, the 
figure is over 80% for the subgroup presenting with IDA.2 
Concerns have been raised about the sensitivity of FIT 
for right- sided CRC,33 and two recent real- world studies 
have confirmed that this is an issue, reporting that about 
10% of all CRCs had a FIT of less than 10 µg Hb/g faeces, 
most of these being right- sided tumours presenting with 
IDA.28 29 An analysis of quantitative FIT results revealed 
median concentrations of 41.6 and 286.8 µg Hb/g faeces 
for right- sided (n=17) and left- sided (n=23) CRCs, respec-
tively (p<0.03).29
A recent systematic review of CRC detection by FIT 
in IDA cohorts yielded five studies with a sensitivity of 
0.82 (95% CI 0.68 to 0.90), though most were small, and 
the evidence quality was poor with a high risk of bias.27 
Further research in this area is warranted, but the provi-
sional conclusion must be that a negative FIT does not 
reliably exclude CRC in the context of IDA. Following 
on from this, it may be safest to regard IDA and FIT as 
complementary indicators of the possibility of underlying 
CRC.
In conclusion, this study has extended previous obser-
vations, confirming that the simple and objective criteria 
of age, sex and Hb are strong and independent predic-
tors of the risk of underlying GI cancer in subjects with 
IDA, and the additional benefit of incorporating MCV 
into the risk stratification model. It has demonstrated 
that in combination these variables can identify 10% of 
the study population who are at ultra- low risk. The devel-
opment of an app based on this model adds practical 
value in a clinical setting.
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